Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection

Award Number: DP2AI176896
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/26/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection - PROJECT SUMMARY Tuberculosis (TB) remains a leading infectious cause of death globally. 1.7 billion people worldwide are estimated to have been infected with TB (LTBI); yet TB infection remains poorly understood. Current LTBI tests cannot distinguish between current infection versus a persistent immune response to a cleared infection and have a low predictive value to identify which people are at risk of developing incident active TB disease. We propose to establish a prospective longitudinal cohort study of health workers (HWs) in Cape Town, South Africa, where our preliminary data reveals HWs have a high annual TB infection risk (34%). This cohort, who will undergo frequent serial evaluation (every 3 months) with a combination of novel assays never previously evaluated together, presents a unique opportunity to evaluate immune responses at the time of initial infection and to characterize the dynamic profile of these immune responses over time in a high-risk population. This interdisciplinary study addresses three knowledge gaps: 1) We will evaluate serial interferon gamma release assay (IGRA) responses to identify early TB infection and characterize the dynamics of IGRA conversion and reversion, which will contribute to understanding of transient versus persistent infection. Furthermore we will elicit HW preferences regarding serial LTBI testing strategies and decision making that will inform the implementation of HW TB screening, which is urgently needed given their occupational TB risk. 2) We will evaluate the temporal dynamics of immune responses to TB by measuring serial RNA biosignatures, C-reactive protein, and Mycobacterium tuberculosis (Mtb)-antibody responses. We will determine whether biosignature results are persistently elevated or wane over time and how these correlate with other measures of immune response. We will be able to comprehensively profile changes in Mtb-antibody responses by not only quantifying IgG levels but by evaluating all isotypes, subclasses and Fc-receptor binding profiles. 3) We will evaluate serial blood samples for detectable Mtb, based on testing of CD34-positive PBMCs and a phage-based assay (Actiphage). Comparing novel Mtb DNA detection approaches could enhance understanding and risk stratification for incident TB in high-risk populations. Our novel data on Mtb immune responses and Mtb quantification in people with LTBI will improve understanding of the correlates of TB immune clearance versus persistence and could help to identify individuals at a higher risk of progression. This study is aligned with the NIAID mission to ‘advance the understanding and diagnosis of re-emerging diseases such as TB’ and to ‘develop international research capacity to respond appropriately to re-emerging disease threats’.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $450,301 )
2026	2026	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Trans-NIH Research Support	003	2	2/26/2026	SUPPLEMENT FOR EXPANSION	$111,645
2026	2026	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Trans-NIH Research Support	002	2	2/23/2026	EXTENSION WITH OR WITHOUT FUNDS	$338,656
2026	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Trans-NIH Research Support	001	1	2/23/2026	NEW	$0
2026	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Trans-NIH Research Support	000	1	2/5/2026	NEW	$0
														Subtotal = $450,301

Issue Date FY: 2023 ( Subtotal = $1,189,520 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Trans-NIH Research Support	000	1	2/16/2023	NEW	$1,189,520
														Subtotal = $1,189,520

Grand Total All Awards = $1,639,821

Top

All Categories

About

Search

Reports

Data Submission

Award Information

THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection

Award Number: DP2AI176896

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/26/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer